Faculty Digital Archive

Archive@NYU >
Stern School of Business >
IOMS: Information Systems Working Papers >

Please use this identifier to cite or link to this item: http://hdl.handle.net/2451/14347

Title: FINANCIAL RISK AND FINANCIAL RISK MANAGEMENT TECHNOLOGY (RMT): ISSUES AND ADVANTAGES
Authors: Bansal, Arun
Kauffman, Robert
Mark, Robert M.
Peters, Edward
Keywords: Risk management
Object-oriented
Neural nets
Artificial intelligence
Business value
Clientserver
Distributed database
Parallel processing
Pattern recognition
Data quality
Issue Date: Aug-1992
Publisher: Stern School of Business, New York University
Series/Report no.: IS-92-31
Abstract: Methods for sound risk management are of increasing interest among Wall Street investment banking and brokerage firms in the aftermath of the October 1987 crash of the stock market. As the knowledge of advanced technology applications in risk management increases, financial firms are finding innovative ways to use them practically, in order to insulate themselves. The recent development in models, the software and hardware, and the market data to track risk are all considered advances in Risk Management Technology (RMT). These advances have affected all three stages of risk management: the identification, the measurement, and the formulation of strategies to control financial risk. This article discusses the advances made in five areas of RMT: communication software, object-oriented programming, parallel processing, neural nets and artificial intelligence. Systems based on any of these areas may be used to add value to the business of a firm. A business value linkage analysis shows how the utility of advanced systems can be measured to justify their costs.
URI: http://hdl.handle.net/2451/14347
Appears in Collections:IOMS: Information Systems Working Papers

Files in This Item:

File Description SizeFormat
IS-92-31.pdf4.77 MBAdobe PDFView/Open

Items in Faculty Digital Archive are protected by copyright, with all rights reserved, unless otherwise indicated.

 

The contents of the FDA may be subject to copyright, be offered under a Creative Commons license, or be in the public domain.
Please check items for rights statements. For information about NYU’s copyright policy, see http://www.nyu.edu/footer/copyright-and-fair-use.html 
Valid XHTML 1.0 | CSS